News GlucoModicum's non-invasive CGM nears first filing Finland's GlucoModicum thinks it is in the lead in the race to bring a non-invasive continuous glucose monitor (CGM) to market.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
